[1]黄盛泉,王建,王佳音,等.分泌粒蛋白Ⅱ在结直肠神经内分泌肿瘤中表达情况和临床分析[J].福建医药杂志,2024,46(02):5-10.[doi:10.20148/j.fmj.2024.02.002]
　HUANG Shengquan,WANG Jian,WANG Jiayin,et al.Expression and clinical analysis of secretory granin Ⅱ in colorectal neuroendo-crine tumors[J].FUJIAN MEDICAL JOURNAL,2024,46(02):5-10.[doi:10.20148/j.fmj.2024.02.002]
点击复制

分泌粒蛋白Ⅱ在结直肠神经内分泌肿瘤中表达情况和临床分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
46
期数:
2024年02期
页码:
5-10
栏目:
临床研究
出版日期:
2024-04-15

文章信息/Info

Title:
Expression and clinical analysis of secretory granin Ⅱ in colorectal neuroendo-crine tumors
文章编号:
1002-2600(2024)02-0005-06
作者:
黄盛泉; 王建; 王佳音; 林娜; 吴春林
福建医科大学附属第二医院病理科,泉州 362000
Author(s):
HUANG Shengquan; WANG Jian; WANG Jiayin; LIN Na; WU Chunlin
Department of Pathology of the Second Affiliated of Fujian Medical University, Quanzhou, Fujian 362000, China
关键词:
结直肠;  神经内分泌肿瘤;  分泌粒蛋白Ⅱ;  免疫组化
Keywords:
colorectal;  neuroendocrine tumor;  secreting granin Ⅱ;  immunohistochemical
分类号:
R735.3
DOI:
10.20148/j.fmj.2024.02.002
文献标志码:
A
摘要:
目的 探讨分泌粒蛋白Ⅱ(secretograninⅡ,SGⅡ)在结直肠神经内分泌肿瘤(colorectal neuroendocrine tumors,CRNETs)中的表达及诊断价值。方法 采用免疫组织化学EnVision两步法检测SGⅡ、突触素(synapsin,Syn)、神经细胞粘附因子(neural cell adhesion molecule,CD56)、嗜铬素A(chromogranin A,CgA)及Ki-67在165例结直肠原发神经内分泌肿瘤(neuroendocrine neoplasms,NENs)及136例非神经内分泌肿瘤(non-neuroendocrine neoplasms,non-NENs)中的表达,比较神经内分泌标记表达的敏感度; 并分析CRNETs中SGⅡ、Ki-67、CgA与临床病理特征的相关性。结果 SGⅡ在CRNETs G1、 G2、G3和NEC中的阳性率分别为97.2%(104/107),100%(40/40),100%(5/5),69.2%(9/13),高于non-NENs(1.47%,7/136)中的阳性率(P<0.05)。SGⅡ在CRNETs中的敏感度为95.8%(158/165),与Syn的98.8%(163/165)相当,高于CD56的84.2%(139/165)及CgA的33.9%(56/165),差异有统计学意义(P<0.05)。肿瘤直径、浸润深度、脉管侵犯、神经侵犯及淋巴结转移与SGⅡ的表达呈负相关,与Ki-67表达呈正相关,差异均有统计学意义(P<0.05),而CgA与以上肿瘤性状呈负相关,差异无统计学意义(P>0.05)。结论 SGⅡ在结直肠神经内分泌肿瘤中高表达,是鉴别诊断CRNETs比较可靠的标志物,其表达与肿瘤直径、浸润深度、脉管侵犯、神经侵犯及淋巴结转移呈负相关。
Abstract:
Objective To investigate the expression and diagnostic value of secretograninⅡ(SGⅡ)in colorectal neuroendocrine tumors(CRNETs).Methods The expression of SGⅡ、Syn、CD56、CgA and Ki-67 were detected using immunohistochemical EnVision two-step method in 165 neuroendocrine neoplasms(NENs)and 136 non-neuroendocrine neoplasms.Results 1)The positive rates of SGⅡ in CRNETs G1, G2, G3 and NEC were 97.2%(104/107), 100%(40/40), 100%(5/5), 69.2%(9/13), respectively.Higher than the positive rate of non-NENs(1.47%, 7/136)(P<0.05); 2)The sensitivity of SGⅡ in CRNETs was 95.8%(158/165), which was similar to Syn(98.8%(163/165), higher than that of CD56(84.2%(139/165)and CgA(33.9%).3)Tumor diameter, invasion depth, vascular invasion, nerve invasion and lymph node metastasis were negatively correlated with SⅡ expression and positively correlated with Ki-67 expression, with statistical significance(P<0.05), while CgA was negatively correlated with the above tumor traits, with no statistical significance(P>0.05).Conclusion SGⅡ is highly expressed in colorectal neuroendocrine tumors, which is a reliable marker for the differential diagnosis of CRNETs.Its expression is negatively correlated with tumor diameter, invasion depth, vascular invasion, nerve invasion and lymph node metastasis.

参考文献/References:

[1] AHMED M.Gastrointestinal neuroendocrine in the tumors in 2020[J].World journal of gastrointestnal oncology,2020,12(8):791-807.
[2] WEILER R,FEICHTINGER H,SCHMID K W,et al.Chromogranin A and B and secretogranin Ⅱ in bronchial and intestinal carcinoids[J].Virchows Arch A Pathol Anat Histopathol,1987,412(2):103-109.
[3] 盛伟琪,周炜洵,陈杰,等.中国胃肠胰神经内分泌肿瘤病理诊断共识(2020版)[J].中华病理学杂志,2021,50(1):14-14.
[4] HUGUET I,GROSSMAN A B,O'TOOLE D.Changes in the epidemiology of neuroendocrine tumours[J].Neuroendocrinology,2017,104(2):105-111.
[5] DASARI A,SHEN C,HALPERIN D,et al.Trends in the incidence,prevalence,and survival outcomes in patients with neuroendocrine tumors in the United States[J].JAMA Oncol,2017,3(10):1335-1342.
[6] 李晓玲,周金钊,王衡,等.177例胃肠神经内分泌肿瘤的临床病理分析[J].广东医科大学学报,2021(3):357-360.
[7] 李燕维,倪慕兰,王宇航.INSM1在消化道神经内分泌肿瘤诊断中的应用价值[J].医学理论与实践,2023(18):3176-3178.
[8] 徐天铭,程小韵,阎鹏光,等.直肠神经内分泌肿瘤临床及病理特征分析[J].中华内科杂志,2021,60(10):886-890.
[9] ISCHIA R,GASSER R W,FISCHER-COLBRIE R,et al.Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients[J].J Clin Endocrinol Metab,2000,85(1):355-360.
[10] Le GALL F,VALLET V S,THOMAS D,et al.Immunohistochemical study of secretogranin Ⅱ in 62 neuroendocrine tumours of the digestive tract and of the pancreas in comparison with other granins[J].Pathol Res Pract,1997,193(3):179-185.
[11] MONTERO-H M,VAINGANKAR S,ELIAS S,et al.Chromogranins A and B and secretogranin Ⅱ:evolutionary and functional aspects[J].Acta Physiol(Oxf),2008,192(2):309-324.
[12] TOPCAGIC J,FELDMAN R,GHAZPLPOUR A,et al.Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas[J].PLoS One,2018,13(1):e0191244.
[13] 廖志晓,邓跃扬,周京旭,等.结直肠神经内分泌肿瘤预后列线图的构建[J].重庆医学,2023,20:3081-3087.
[14] 闫玉玲.Syn、CgA、Ki67在胃肠胰神经内分泌肿瘤患者中的表达及其与临床特征的相关性[J].中国民康医学,2021(19):1-4.
[15] PORTELA-G G M,STRIDSBERG M,GRIMELIUS L,et al.Expression of chromogranins A,B,and C(secretogranin Ⅱ)in human adrenal medulla and in benign and malignant pheochromocytomas an immunohistochemical study with region-specific antibodies[J].APMIS,2004,112(10):663-673.
[16] AL-RISI E S,AL-ESSRY F S,MULA-ABED W S.Chromogranin A as a biochemical marker for neuroendocrine tumors:a single center experience at Royal Hospital[J].Oman Med J,2017,32(5):365-370.
[17] YOO S H,CHU S Y,KIM K D,et al.Presence of secretogranin Ⅱ and high-capacity,low-affinity Ca2+ storage role in nucleoplasmic Ca2+ store vesicles[J].Biochemistry,2007,46(50):14663-14671.
[18] PARK H Y,SO S H,LEE W B,et al.Purification,pH-dependent conformational change,aggregation,and secretory granule membrane binding property of secretogranin Ⅱ(chromogranin C)[J].Biochemistry,2002,41(4):1259-1266.
[19] STRIDSBERG M,ERIKSSON B,JANSON E T.Measure-ments of secretogranins Ⅱ,Ⅲ,Ⅳ and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours[J].Regul Pept,2008,148(1/3):95-98.

备注/Memo

备注/Memo:
通信作者:吴春林,Email:wuchunlin120@sina.com
更新日期/Last Update: 2024-04-15